EP2228064

NOVARTIS AG
Application Number
EP10164976A
Filing Date
May 17, 2005
Status
Granted And Under Opposition
Nov 8, 2019
Grant Date
Dec 11, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2228064B1 was granted on Dec 11, 2019 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 10 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR. SCHON, NEYMEYR & PARTNER PATENTANWALTE MBBSep 11, 2020ADMISSIBLE
EUROPEAN OPPOSITIONS LIMITEDSep 11, 2020ADMISSIBLE
HGF LIMITEDSep 11, 2020ADMISSIBLE
ISARPATENT - PATENT- UND RECHTSANWALTE BEHNISCH BARTH CHARLES HASSA PECKMANN UND PARTNER MBBSep 11, 2020ADMISSIBLE
N.V. NEDERLANDSCH OCTROOIBUREAUSep 11, 2020ADMISSIBLE
STADASep 11, 2020ADMISSIBLE
ORION CORPORATION ORION PHARMASep 11, 2020WITHDRAWN
PGA S.P.A.Sep 10, 2020WITHDRAWN
TEVASep 8, 2020ADMISSIBLE
HOFFMANN EITLESep 8, 2020WITHDRAWN

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.